Drotrecogin alfa (activated): A novel therapeutic strategy for severe sepsis Journal Article


Author: Pastores, S. M.
Article Title: Drotrecogin alfa (activated): A novel therapeutic strategy for severe sepsis
Abstract: Recent studies have highlighted the close link between activation of the coagulation system and the inflammatory response in the pathophysiology of severe sepsis. The protein C anticoagulant pathway plays an integral part in modulating the coagulation and inflammatory responses to infection. In patients with sepsis, endogenous protein C levels are decreased, shifting the balance toward greater systemic inflammation, coagulation, and cell death. On the basis of a single large randomised phase 3 trial, drotrecogin alfa (activated), a recombinant form of human activated protein C, was recently approved for the treatment of adult patients with severe sepsis and a high risk of death. Since its approval, several questions have been raised regarding the appropriate use of this agent. Given the increased risk of serious bleeding and the high cost of treatment, drotrecogin alfa (activated) should be reserved at this time for the most acutely ill patients with severe sepsis who meet the criteria that were used in the phase 3 trial.
Keywords: clinical feature; clinical trial; review; gastrointestinal hemorrhage; treatment planning; pathophysiology; cell death; bleeding; inflammation; risk factor; drug cost; disease severity; acetylsalicylic acid; nonsteroid antiinflammatory agent; recombinant proteins; warfarin; heparin; sepsis; drug contraindication; brain hemorrhage; clinical trials; antithrombocytic agent; low molecular weight heparin; drug indication; blood clotting; blood coagulation; anti-infective agents; protein c; drotrecogin; humans; human
Journal Title: Postgraduate Medical Journal
Volume: 79
Issue: 927
ISSN: 0032-5473
Publisher: BMJ Publishing Group Ltd.  
Date Published: 2003-01-01
Start Page: 5
End Page: 10
Language: English
DOI: 10.1136/pmj.79.927.5
PUBMED: 12566544
PROVIDER: scopus
PMCID: PMC1742596
DOI/URL:
Notes: Export Date: 25 September 2014 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Stephen Pastores
    250 Pastores